Advances in Breast Cancer Care: The Role of Artificial Intelligence and Digital Pathology in Precision Medicine
- PMID: 40028897
- PMCID: PMC11934827
- DOI: 10.4274/ejbh.galenos.2025.2024-12-8
Advances in Breast Cancer Care: The Role of Artificial Intelligence and Digital Pathology in Precision Medicine
Abstract
Artificial intelligence (AI) and digital pathology are transforming breast cancer management by addressing the limitations inherent in traditional histopathological methods. The application of machine learning algorithms has enhanced the ability of AI systems to classify breast cancer subtypes, grade tumors, and quantify key biomarkers, thereby improving diagnostic accuracy and prognostic precision. Furthermore, AI-powered image analysis has demonstrated superiority in detecting lymph node metastases, contributing to more precise staging, treatment planning, and reduced evaluation time. The ability of AI to predict molecular markers, including human epidermal growth factor receptor 2 status, BRCA mutations and homologus recombination deficiency, offers substantial potential for the development of personalized treatment strategies. A collaborative approach between pathologists and AI systems is essential to fully harness the potential of this technology. Although AI provides automation and objective analysis, human expertise remains indispensable for the interpretation of results and clinical decision-making. This partnership is anticipated to transform breast cancer care by enhancing patient outcomes and optimizing treatment approaches.
Keywords: AI; Artificial intelligence; breast cancer; pathology.
©Copyright 2025 by the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.
Conflict of interest statement
Conflict of Interest: No conflict of interest declared by the authors.
Similar articles
-
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence.Cancers (Basel). 2024 May 23;16(11):1981. doi: 10.3390/cancers16111981. Cancers (Basel). 2024. PMID: 38893102 Free PMC article. Review.
-
Artificial intelligence's impact on breast cancer pathology: a literature review.Diagn Pathol. 2024 Feb 22;19(1):38. doi: 10.1186/s13000-024-01453-w. Diagn Pathol. 2024. PMID: 38388367 Free PMC article. Review.
-
Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.Breast Cancer Res. 2024 Feb 23;26(1):31. doi: 10.1186/s13058-024-01784-y. Breast Cancer Res. 2024. PMID: 38395930 Free PMC article.
-
Artificial Intelligence in Thoracic Surgery: A Review Bridging Innovation and Clinical Practice for the Next Generation of Surgical Care.J Clin Med. 2025 Apr 16;14(8):2729. doi: 10.3390/jcm14082729. J Clin Med. 2025. PMID: 40283559 Free PMC article. Review.
-
Impact of artificial intelligence on prognosis, shared decision-making, and precision medicine for patients with inflammatory bowel disease: a perspective and expert opinion.Ann Med. 2023;55(2):2300670. doi: 10.1080/07853890.2023.2300670. Epub 2024 Jan 1. Ann Med. 2023. PMID: 38163336 Free PMC article. Review.
References
-
- Knoop AS, Lænkholm AV, Jensen MB, Nielsen KV, Andersen J, Nielsen D, et al. Estrogen receptor, progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. Eur J Cancer. 2014;50(8):1412–14121. doi: 10.1016/j.ejca.2014.02.022. - DOI - PubMed
-
- Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. doi: 10.1016/s1470-2045(17)30904-x. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials